Neuromuscular

In an AAN plenary talk, Mark H. Tuszynski, MD, PhD, detailed the work he and colleagues have done to push stem cell therapy from the lab to the clinic to improve care for spinal cord injury.

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending April 17, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 16, 2021.

The ability to feed orally and swallow was maintained by an overwhelming number of patients treated with risdiplam at 24 months.

According to the study authors, future longitudinal studies assessing the evolution of cognitive and cortical excitability changes may provide a greater understanding of the importance of cortical circuits in ALS pathogenesis.

The 2021 AAN Annual Meeting will be held virtually from April 17-22. Follow along with coverage from NeurologyLive, including expert interviews and session recaps.

At 6 months, 62% of the 10 kHz spinal cord stimulation treatment group had observed improvement upon investigator-assessed neurological examination, compared to 3% of conventional medical management subjects.

Here's what is coming soon to NeurologyLive.

Researchers used patient, family, and public engagement to develop a 14-item DMD-QoL questionnaire.

Neurology News Network for the week ending April 10, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 9, 2021.

Antisense-mediated reduction of mutant FUS protein previously showed prevention of motor neuron loss in an FUS-ALS mouse model.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Bhooma Aravamuthan, MD, DPhil.

A majority of patients across all 3 cohorts maintained or improved their motor function shown by changes from baseline in Revised Hammersmith Scale scores.

A case report showed 1 patient in the vaccine arm developed Guillain-Barré syndrome, though 1 in the placebo arm also developed the syndrome, implying coincidence rather than causation.

Overall, 91% of participants in the pooled bimagrumab group and 89.1% in the placebo group had at least 1 or more treatment-emergent adverse event.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 2, 2021.

An update on the phase 1b study of Pfizer’s investigational DMD treatment was presented at the MDA 2021 conference.

Researchers conducted a post-hoc analysis of Study 19 to determine hazard ratios of milestone occurrences in amyotrophic lateral sclerosis.

A recent publication describes the findings of two initiatives to evaluate and raise awareness about the impact that SMA has on adolescents and young adults.

Preliminary results from the IGNITE-DMD trial also showed a decreased in creatine kinase levels and improvements on NSAA and PODCI.

Here's what is coming soon to NeurologyLive.

The Adults with SMA Virtual Therapy Program is sponsored by Genentech and the Dhont Family Foundation.

Researchers observed improvements in motor and respiratory function and biomarkers in the investigational treatment group.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 26, 2021.

The VBP-LTE study found no evidence of slowed linear growth, insulin resistance, or osteocalcin decreases.

The senior vice president and chief medical officer at Novartis Gene Therapies shared his perspective on the recent clinical trial results for Zolgensma in SMA type 1.